🧬💊🛡️ Bictegravir 50mg + Emtricitabine 200mg + Tenofovir Alafenamide 25mg Tablet: A Complete Once-Daily HIV Regimen
The fixed-dose combination of Bictegravir (50mg) + Emtricitabine (200mg) + Tenofovir Alafenamide (25mg) is a once-daily, single-tablet regimen used in the treatment of HIV-1 infection in adults and adolescents. It offers a potent, well-tolerated, and convenient antiretroviral therapy (ART) option that suppresses viral load, improves immune function, and reduces the risk of HIV transmission.
This regimen is recommended as a first-line treatment by many international guidelines due to its high efficacy, minimal drug interactions, and low risk of resistance development.
🔬 Mechanism of Action
This tablet combines three antiretroviral agents from two classes:
🔹 Bictegravir (50mg) – Integrase Strand Transfer Inhibitor (INSTI)
-
Blocks the HIV integrase enzyme, preventing viral DNA from integrating into the host cell genome
-
Offers high barrier to resistance and excellent viral suppression
🔹 Emtricitabine (200mg) – Nucleoside Reverse Transcriptase Inhibitor (NRTI)
-
Mimics cytidine and gets incorporated into viral DNA
-
Inhibits the reverse transcriptase enzyme, blocking viral replication
🔹 Tenofovir Alafenamide (25mg) – Nucleotide Reverse Transcriptase Inhibitor (NRTI)
-
Prodrug of Tenofovir; more targeted delivery to lymphoid cells
-
Lower systemic exposure = reduced kidney and bone toxicity
Together, these agents provide triple antiretroviral coverage, making the regimen effective for rapid viral suppression and durable control of HIV.
📌 Indications and Uses
-
Treatment of HIV-1 infection in:
-
Adults and adolescents ≥12 years weighing ≥25 kg
-
Treatment-naïve patients
-
Patients virologically suppressed (HIV RNA <50 copies/mL) on a stable ART regimen for ≥3 months
-
This combination is not indicated for hepatitis B monoinfection, though it may help suppress HBV in coinfected patients.
💊 Dosage and Administration
-
One tablet once daily, with or without food
-
Take at the same time every day
-
Do not chew or crush the tablet
⚠️ Precautions and Warnings
-
Renal function monitoring is recommended, especially in patients with renal impairment
-
Avoid use with rifampin and other potent inducers of CYP3A or UGT1A1
-
Use with caution in patients co-infected with Hepatitis B—sudden discontinuation may cause HBV flare
-
Not recommended during pregnancy unless no alternatives are available (limited data)
🤒 Side Effects
Common:
-
Headache
-
Nausea
-
Diarrhea
-
Fatigue
-
Dizziness
Serious (rare):
-
Lactic acidosis
-
Liver problems
-
Worsening of hepatitis B infection
-
Immune reconstitution inflammatory syndrome (IRIS)
Most patients tolerate this therapy well.
🔄 Drug Interactions
-
Avoid with:
-
Rifampin, rifabutin
-
Carbamazepine, phenobarbital, phenytoin
-
-
Caution with antacids (separate dosing times by several hours due to Bictegravir)
🧊 Storage Instructions
-
Store at 20–25°C, away from moisture and heat
-
Keep in original container, tightly closed
-
Keep out of reach of children
📝 Conclusion
Bictegravir + Emtricitabine + Tenofovir Alafenamide is a comprehensive, once-daily HIV treatment that simplifies therapy without compromising potency or safety. Its excellent tolerability, high genetic barrier to resistance, and favorable side-effect profile make it a cornerstone in modern HIV management, helping patients live longer, healthier lives with effective viral suppression.
Always follow your doctor’s advice, dosage instructions, and never self-medicate.
Note: This information is intended for educational purposes and should not replace professional medical advice. Always consult your healthcare provider for personalized recommendations.
Reviews
There are no reviews yet.